WO2021037292A3 - 一种多肽及其应用 - Google Patents

一种多肽及其应用 Download PDF

Info

Publication number
WO2021037292A3
WO2021037292A3 PCT/CN2020/123555 CN2020123555W WO2021037292A3 WO 2021037292 A3 WO2021037292 A3 WO 2021037292A3 CN 2020123555 W CN2020123555 W CN 2020123555W WO 2021037292 A3 WO2021037292 A3 WO 2021037292A3
Authority
WO
WIPO (PCT)
Prior art keywords
fibrosis
arg
polypeptide
cys
gly
Prior art date
Application number
PCT/CN2020/123555
Other languages
English (en)
French (fr)
Other versions
WO2021037292A2 (zh
Inventor
康志安
Original Assignee
南京安吉生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南京安吉生物科技有限公司 filed Critical 南京安吉生物科技有限公司
Priority to AU2020335069A priority Critical patent/AU2020335069A1/en
Priority to GB2201001.1A priority patent/GB2600592A/en
Priority to CA3149603A priority patent/CA3149603A1/en
Priority to US17/635,990 priority patent/US20220281916A1/en
Publication of WO2021037292A2 publication Critical patent/WO2021037292A2/zh
Publication of WO2021037292A3 publication Critical patent/WO2021037292A3/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明提供了一种多肽及其应用，属于生物制药领域。该多肽中含有的结构域Pro-Arg-Cys-X-Y-Gly-Glu和Arg-Gly-Ala-Asp-Arg-Ala,其中X是Trp或Tyr，Y是Arg或Cys;可以治疗各种纤维化疾病及病状，包括肺纤维化、肝纤维化、骨髓纤维化、肾纤维化和心肌纤维化、皮肤纤维化以及肺部组织病变。
PCT/CN2020/123555 2019-08-27 2020-10-26 一种多肽及其应用 WO2021037292A2 (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2020335069A AU2020335069A1 (en) 2019-08-27 2020-10-26 Polypeptide and use thereof
GB2201001.1A GB2600592A (en) 2019-08-27 2020-10-26 Polypeptide and use thereof
CA3149603A CA3149603A1 (en) 2019-08-27 2020-10-26 Polypeptide and use thereof
US17/635,990 US20220281916A1 (en) 2019-08-27 2020-10-26 Polypeptide and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910799291.8A CN110437311B (zh) 2019-08-27 2019-08-27 一种多肽及其应用
CN201910799291.8 2019-08-27

Publications (2)

Publication Number Publication Date
WO2021037292A2 WO2021037292A2 (zh) 2021-03-04
WO2021037292A3 true WO2021037292A3 (zh) 2021-04-22

Family

ID=68437902

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/123555 WO2021037292A2 (zh) 2019-08-27 2020-10-26 一种多肽及其应用

Country Status (6)

Country Link
US (1) US20220281916A1 (zh)
CN (1) CN110437311B (zh)
AU (1) AU2020335069A1 (zh)
CA (1) CA3149603A1 (zh)
GB (1) GB2600592A (zh)
WO (1) WO2021037292A2 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110437311B (zh) * 2019-08-27 2022-05-20 南京安吉生物科技有限公司 一种多肽及其应用
CN116789751B (zh) * 2023-08-22 2023-11-17 中国农业大学 预防和/或治疗纤维化疾病的多肽及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008023336A2 (en) * 2006-08-22 2008-02-28 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
CN102268068A (zh) * 2011-07-01 2011-12-07 中国药科大学 基质金属蛋白酶-9多肽抑制剂1及其应用
CN102268070A (zh) * 2011-07-01 2011-12-07 中国药科大学 基质金属蛋白酶-9多肽抑制剂2及其应用
CN104045718A (zh) * 2014-07-08 2014-09-17 南京安吉生物科技有限公司 多功能融合多肽及其制备方法和应用
CN110437311A (zh) * 2019-08-27 2019-11-12 南京安吉生物科技有限公司 一种多肽及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105713095B (zh) * 2016-03-14 2021-05-07 南京安吉生物科技有限公司 一种多功能融合多肽及其制备方法和应用
CN106860855B (zh) * 2017-03-01 2021-06-11 成都惠泰生物医药有限公司 多肽及多肽衍生物在预防和治疗纤维化疾病中的应用
CN109384830B (zh) * 2017-08-09 2021-12-03 成都惠泰生物医药有限公司 多肽、多肽片段及其衍生物在防治纤维化疾病中的应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008023336A2 (en) * 2006-08-22 2008-02-28 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
CN102268068A (zh) * 2011-07-01 2011-12-07 中国药科大学 基质金属蛋白酶-9多肽抑制剂1及其应用
CN102268070A (zh) * 2011-07-01 2011-12-07 中国药科大学 基质金属蛋白酶-9多肽抑制剂2及其应用
CN104045718A (zh) * 2014-07-08 2014-09-17 南京安吉生物科技有限公司 多功能融合多肽及其制备方法和应用
CN110437311A (zh) * 2019-08-27 2019-11-12 南京安吉生物科技有限公司 一种多肽及其应用

Also Published As

Publication number Publication date
CA3149603A1 (en) 2021-03-04
AU2020335069A1 (en) 2022-03-10
GB202201001D0 (en) 2022-03-09
WO2021037292A2 (zh) 2021-03-04
CN110437311B (zh) 2022-05-20
GB2600592A (en) 2022-05-04
US20220281916A1 (en) 2022-09-08
CN110437311A (zh) 2019-11-12

Similar Documents

Publication Publication Date Title
WO2021037292A3 (zh) 一种多肽及其应用
US10568938B2 (en) Mussel adhesive protein product and applications thereof in suppression of skin inflammations
WO2002002593A3 (en) Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
EP3801235A4 (en) PROCEDURE FOR VISUALIZING BODY SURFACE OF A PATIENT AND DETERMINING COORDINATES OF ECG ELECTRODES DURING NON-INVASIVE ELECTROPHYSIOLOGICAL IMAGING OF THE HEART
CN100374093C (zh) 无柄人工髋关节装置
WO2021037289A3 (zh) 一种重组融合多肽及其应用
ZA202201828B (en) Therapeutic fusion proteins
Harken A review of the activities of the thoracic center for the III and IV hospital groups, 160th General Hospital European Theater of Operations, June 10, 1944 to Jan. 1, 1945
WO2021037291A3 (zh) 具有多功能活性的融合多肽及其应用
US11260111B2 (en) Mussel adhesive protein product and applications thereof in suppression of skin inflammations
WO2020198662A8 (en) Clec9a-based chimeric protein complexes
Weißer Chirurgenlexikon
CN209285708U (zh) 双极电凝
Abdullaeva Introduction to biomaterials
CN204500945U (zh) 一体式导流吸引双极电凝钳
CN209461018U (zh) 一种段间标志点量化的肺段魔方
Zamboni et al. Hemodynamics and volume changes of the venous system
Hashimoto Double-orifice mitral valve with three papillary muscles
Huang et al. A Method to Facilitate “Nonsticking” of Regular Bipolar Forceps
Karami et al. Burn Escharotomy
CN208388857U (zh) 一种膏药贴结构
CN109248285A (zh) 一种治疗鼻炎用软膏剂
ITMI991526A0 (it) Apparecchiatura per determinare ed ablare il volume del tessuto cornea le per correggere le ametropie visive
Lakkireddy et al. Advances in Electrophysiology
CN204542828U (zh) 一种多功能按摩器

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20856111

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 202201001

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20201026

ENP Entry into the national phase

Ref document number: 3149603

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020335069

Country of ref document: AU

Date of ref document: 20201026

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 20856111

Country of ref document: EP

Kind code of ref document: A2